Abstract
Enzyme-replacement therapy (ERT) with alglucosidase alfa has become standard of care in the treatment of patients with Pompe disease and is known to benefit walking ability, muscle strength and respiratory function in studies up to 5 years' follow-up. The aim of this study was to determine the effects of 10 years' ERT, focusing on individual variability in treatment response.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
